Fellowship, Hematology/Oncology, University of Connecticut - Health Center, Farmington, CT
1999:
Residency, Internal Medicine, University of Connecticut - Health Center, Farmington, CT
1997:
Internship, Internal Medicine, University of Connecticut - Health Center, Farmington, CT
1994:
MD, University of the Punjab - King Edward Medical College, Lahore, Punjab, Pakistan
1987:
Cadet College Hasan Abdal, Pakistan
Work Experience
2004 to Present:
Attending Physician, MCHS Hospitals Inc. d/b/a Marshfield Medical Center
2004 to Present:
Attending Physician, Marshfield Clinic Inc. - Chippewa Falls Center, Chippewa Falls, WI
2002 to 2004:
Consultant Oncologist, Shaukat Khanum Cancer Hospital & Research Center, Lahore, Pakistan
1994 to 1995:
Internal Medicine, Mayo Hospital, Lahore, Pakistan
1994 to 1994:
General Surgery, Mayo Hospital, Lahore, Pakistan
Board Certifications
2004 to 2024:
American Board of Internal Medicine - Hematology (2004), Recertified
Professional Societies
American Society of Clinical Oncology
American Society of Hematology
Select Publications
Bilgrami S, Edwards RL, Bona RD, Kazierad D, Furlong F, Fox JG,...Tutschka PJ. (2000). A pilot study of busulfan, cyclophosphamide and etoposide followed by autologous transplantation for acute myeloid leukemia in remission. Acta Haematol. 104(2-3):144-147.
PubMed ID:
11154994
Tutschka PJ, Bilgrami SA, Feingold JM, Edwards RL, Bona RD, Naqvi BH, Clive J. (2001 August). Cytoreduction and stem cell mobilization with a regimen of paclitaxel, etoposide and cyclophosphamide followed by autologous transplantation using a preparative regimen of busulfan, etoposide and cyclophosphamide for patients with advanced lymphoma. Acta Haematol. 105(4):222-232.
Bilgrami S, Bona RD, Edwards RL, Li Z, Naqvi BH, Shaikh S,...Tutschka PJ. (2001 July). Dexamethasone, paclitaxel, etoposide, cyclophosphamide (d-TEC) and G-CSF for stem cell mobilisation in multiple myeloma. Bone Marrow Transplant. 28(2):137-143.
PubMed ID:
11509931
Tutschka PJ, Bilgrami S, Feingold JM, Edwards RL, Bona RD, Naqvi BH, Clive J. (2001). Cytoreduction and stem cell mobilization with a non-ablative high intensity chemotherapy regimen of paclitaxel, etoposide, and cyclophosphamide (D-TEC) followed by autologous transplantation using an ablative high intensity preparative regimen of busulfan, etoposide and cyclophosphamide (BuCET) for patients with advance lymphoma Acta Hemato. 105(4):222-232.
PubMed ID:
11528096
Naqvi BH, Dorsky D, Ali SA, Feingold JM, Edwards RL, Bona RD,...Bilgrami S. (2001 August). Efficacy of clarithromycin in preventing viridans streptococcal bacteremia following autologous stem cell transplantation Infection. 29(4):201-204.
PubMed ID:
11545480
Bilgrami S, Metersky ML, McNally D, Naqvi BH, Kapur D, Raible D,...Tutschka PJ. (2001 February). Idiopathic pneumonia syndrome following myeloablative chemotherapy and autologous transplantation. Ann Pharmacother. 35(2):196-201.
PubMed ID:
11215840
Badar F, Moid I, Waheed F, Zaidi A, Naqvi BH, Yunus S. (2005 January). Variables associated with recurrence in breast cancer patients-the Shaukat Khanum Memorial experience. Asian Pac J Cancer Prev. 6(1):54-57.
PubMed ID:
15780033
Badar F, Moid I, Waheed F, Zaidi A, Naqvi BH, Yunus S. (2005 June). Survival analyses of breast cancer patients--the Shaukat Khanum Memorial experience. Asian Pac J Cancer Prev. 6(2):135-138.
PubMed ID:
16101321
Rashid MU, Zaidi A, Torres D, Sultan F, Brenner A, Naqvi BH,...Hamann U. (2006 December). Prevalence of BRCA1 and BRCA2 mutations in Pakistani breast and ovarian cancer patients. Int J Cancer. 119(12):2832-2839.
PubMed ID:
16998791